Old Dominion Freight Line Announces $0.15 Per Share Quarterly Cash Dividend

Oxford Vaccine Gets $1 Billion; Surge in Brazil: Virus Update

(Bloomberg) -- Global coronavirus cases topped five million, doubling in the past month, and infections rose at a record pace in Brazil and Indonesia. AstraZeneca received $1.2 billion in U.S. funding to develop a vaccine, while CanSino Biologics signed a deal to test and sell a Canadian vaccine candidate.U.S. President Donald Trump suggested Chinese leader Xi Jinping was behind a “disinformation and propaganda attack,” and is set to tour Ford’s ventilator facility on Thursday. Cases stabilized in Russia and the emergency in Tokyo may soon be lifted.The euro-area economy started to claw its way out of its downturn and U.S. jobless claims will probably continue to trend lower. The U.S. Transportation Security Administration has started making changes to airport screening and EasyJet said it plans to resume flights from some European airports in June.Key Developments:Virus Tracker: Cases reached 5 million; deaths exceed 328,000Why a new cluster in China is triggering alarms:...

AstraZeneca Can Make Up To 1B Covid-19 Vaccine Doses, Signs First Supply Pacts

UK-based pharmaceutical company AstraZeneca Plc (AZN) on Thursday disclosed that it has the capacity to produce 1 billion doses of its coronavirus vaccine should it prove to be successful. The stock rose 3.5% to $55.65 in pre-market U.S. trading.The drugmaker said it has signed first agreements for at least 400 million doses and has secured total manufacturing capacity for one billion doses of the potential vaccine, which it is developing with Oxford University. Start of deliveries are planned for September 2020, the company said in a statement.AstraZeneca is also working on entering into additional agreements supported by several parallel supply chains, which is aimed at expanding capacity further over the next months to ensure the delivery of a globally accessible vaccine, the company said.All of this though will be dependent on getting data results from the vaccine candidate’s Phase I/II clinical trial, which the drugmaker expects shortly and if positive, would...